ANNA GIEMZA-PALMER: Open Payments
NPI 1427415553 · DRIGGS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$144 in 7 payments from 6 companies in 2025. Trend: 2023 $91 · 2024 $196 · 2025 $144
Food & beverage: $144
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, INGREZZA, ABILIFY ASIMTUFII, SUBLOCADE.
Industry payments across ID — which companies pay providers there.
